Daclatasvir dihydrochloride - CAS 1009119-65-6
Catalog number: B0084-454273
Category: Inhibitor
Please be kindly noted products are not for therapeutic use. We do not sell to patients.
Molecular Formula:
C40H50N8O6·2HCl
Molecular Weight:
811.8
COA:
Inquire
Targets:
HCV
Description:
Daclatasvir is a highly selective inhibitor of HCV NS5A with EC50 of 9-50 pM, for a broad range of HCV replicon genotypes and the JFH-1 genotype 2a infectious virus in cell culture.
Ordering Information
Catalog Number Size Price Stock Quantity
B0084-454273 5 g $398 In stock
Bulk Inquiry
Purity:
>98%
Related CAS:
1009119-64-5
Appearance:
Solid Powder
Synonyms:
Methyl N-[(2S)-1-[(2S)-2-[5-[4-[4-[2-[(2S)-1-[(2S)-2-(methoxycarbonylamino)-3-methylbutanoyl]pyrrolidin-2-yl]-1H-imidazol-5-yl]phenyl]phenyl]-1H-imidazol-2-yl]pyrrolidin-1-yl]-3-methyl-1-oxobutan-2-yl]carbamate dihydrochloride; Daclatasvir; BMS790052; BMS 790052; BMS-790052; EBP883; EBP 883; EBP-883; Daklinza
MSDS:
Inquire
InChIKey:
BVZLLUDATICXCI-JMSCDMLISA-N
InChI:
InChI=1S/C40H50N8O6.2ClH/c1-23(2)33(45-39(51)53-5)37(49)47-19-7-9-31(47)35-41-21-29(43-35)27-15-11-25(12-16-27)26-13-17-28(18-14-26)30-22-42-36(44-30)32-10-8-20-48(32)38(50)34(24(3)4)46-40(52)54-6;;/h11-18,21-24,31-34H,7-10,19-20H2,1-6H3,(H,41,43)(H,42,44)(H,45,51)(H,46,52);2*1H/t31-,32-,33-,34-;;/m0../s1
Canonical SMILES:
CC(C)C(C(=O)N1CCCC1C2=NC=C(N2)C3=CC=C(C=C3)C4=CC=C(C=C4)C5=CN=C(N5)C6CCCN6C(=O)C(C(C)C)NC(=O)OC)NC(=O)OC.Cl.Cl
1.Synthesis of isotopically labeled daclatasvir for use in human clinical studies.
Easter JA;Burrell RC;Bonacorsi SJ Jr J Labelled Comp Radiopharm. 2016 Apr;59(4):164-70. doi: 10.1002/jlcr.3386. Epub 2016 Mar 10.
Daclatasvir is a novel hepatitis C virus NS5A inhibitor developed by Bristol-Myers Squibb and marketed as Daklinza®. The need to support the development of daclatasvir required the synthesis of carbon-14 labeled material for use in human absorption, distribution, metabolism, and excretion studies. A total of 7.53 mCi of [(14) C]-daclatasvir was synthesized in eight steps from commercially available [(14) C]-copper cyanide. The radiochemical purity was 99.6%, and specific activity was 3.86 μCi/mg. To support a human absolute bioavailability study, 5.56 g of [(13) C2 , (15) N4 ]-daclatasvir was synthesized in four steps.
2.Daclatasvir: A Review in Chronic Hepatitis C.
Keating GM Drugs. 2016 Sep;76(14):1381-91. doi: 10.1007/s40265-016-0632-x.
The hepatitis C virus (HCV) NS5A replication complex inhibitor daclatasvir (Daklinza(®)) is indicated for use in combination with sofosbuvir, with or without ribavirin, in a pangenotypic all-oral regimen. In patients with chronic HCV genotype 1 or 3 infection without cirrhosis, a 12-week regimen of daclatasvir plus sofosbuvir achieved high sustained virological response rates 12 weeks' post-treatment (SVR12), regardless of prior treatment experience, according to the results of the AI444040 and ALLY-3 trials. In the ALLY-3+ trial, high SVR12 rates were achieved with a 12- or 16-week regimen of daclatasvir plus sofosbuvir and ribavirin in patients with chronic HCV genotype 3 infection and advanced fibrosis or compensated cirrhosis. A daclatasvir plus sofosbuvir-based regimen demonstrated efficacy in patients with chronic HCV genotype 1, 3 or 4 infection and advanced cirrhosis or post-transplant recurrence in the ALLY-1 trial, and in patients co-infected with HCV genotype 1, 3 or 4 and HIV-1 in the ALLY-2 trial. Results of clinical trials were supported by real-world data from early-access programmes that included high numbers of patients who would have been excluded from phase 3 trials because of advanced disease and/or concomitant medical conditions.
3.Pharmaceutical Approval Update.
Gohil K P T. 2015 Oct;40(10):649-89.
Alirocumab (Praluent) for high cholesterol; flibanserin (Addyi) for sexual desire disorder in women; daclatasvir (Daklinza) for chronic hepatitis C virus (HCV) genotype 3 infection; and ombitasvir/paritaprevir/ritonavir (Technivie) for genotype 4 HCV infection without cirrhosis.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related HCV Products


CAS 1098189-15-1 Vedroprevir

Vedroprevir
(CAS: 1098189-15-1)

Vedroprevir is a selective hepatitis C virus (HCV) NS3 protease inhibitor. It is a pharmaceutical drug that is used in the treatment of hepatitis C virus in pat...

CAS 1377049-84-7 Velpatasvir

Velpatasvir
(CAS: 1377049-84-7)

Velpatasvir is a selective Hepatitis C virus NS 5 protein inhibitor originated by Gilead Sciences. It showed pan-genotypic activity and a high barrier to resist...

CAS 923590-37-8 Vaniprevir

Vaniprevir
(CAS: 923590-37-8)

Vaniprevir is a non-covalent competitive inhibitor of the hepatitis C virus (HCV) NS3/4A protease. It is a macrocyclic hepatitis C virus NS3/4a protease inhibit...

CAS 81485-25-8 Peretinoin

Peretinoin
(CAS: 81485-25-8)

Peretinoin, also known as NIK-333, orally available, acyclic retinoid with potential antineoplastic and chemopreventive activities. Peretinoin binds to and acti...

CAS 1258226-87-7 Ombitasvir

Ombitasvir
(CAS: 1258226-87-7)

Ombitasvir, a NS5A inhibitor, could be effective in the treatment of HCV as an antiviral agent. IC50: 14 pM and 5 pM (EC50) for genotype 1a-H77 and 1b-Con1 resp...

CAS 817204-33-4 PSI-6130

PSI-6130
(CAS: 817204-33-4)

PSI-6130 is a potent and selective inhibitor of HCV NS5B polymerase. It is metabolized to two pharmacologically active species in primary human hepatocytes.

CAS 1350462-55-3 MK-5172 hydrate

MK-5172 hydrate
(CAS: 1350462-55-3)

In biochemical assays, MK-5172 was effective against a panel of major genotypes and variants engineered with common resistant mutations observed in clinical stu...

CAS 36791-04-5 Ribavirin

Ribavirin
(CAS: 36791-04-5)

Ribavirin is a guanosine (ribonucleic) analog used to stop viral RNA synthesis and viral mRNA capping, thus, it is a nucleoside inhibitor.

Chemical Structure

CAS 1009119-65-6 Daclatasvir dihydrochloride

Quick Inquiry

Verification code

Featured Items